SubsidieMeestersARISE - Advanced RNA Inhalation Solutions anchored in Evolved dry powder technology.
RNhale's project aims to revolutionize RNA therapeutics for pulmonary diseases by developing inhalable dry powder formulations of RNA encapsulated in lipid nanoparticles.
Projectdetails
Introduction
One of the main challenges in the domain of respiratory RNA delivery has been administration. Today, while 15 RNA therapeutics are undergoing clinical trials for pulmonary diseases, none has yet secured regulatory approval.
Innovative Approach
Our nano-embedded microparticles (NEMs) represent a disruptive approach and paradigm shift in the field of RNA therapeutics for the treatment of pulmonary diseases. Our IP-protected NEM technology comprises therapeutic RNA, which is encapsulated in lipid nanoparticles (LNPs) and formulated as an inhalable dry powder.
Business Concept
This innovation builds the foundation to RNhale's two-pronged business concept:
- In-house drug development
- RNA formulation in R&D partnerships
Drug Development
In brief, we have developed a standalone approach, pioneering an RNAi-based drug candidate for the treatment of moderate and severe allergic asthma.
Production Technology
Additionally, our scalable and indication-independent production technology of RNA-loaded dry powders will be a second mainstay of our commercialization strategy.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.421.498 |
| Totale projectbegroting | € 2.421.498 |
Tijdlijn
| Startdatum | 1-4-2025 |
| Einddatum | 31-3-2028 |
| Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- RNhale GmbHpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
TraffikGene-Tx: Targeted Peptide Carriers for RNA DeliveryTraffikGene-Tx aims to develop safe, scalable peptide carriers for targeted RNA delivery, addressing genetic diseases and enhancing NAT therapies to improve patient outcomes and reduce healthcare costs. | EIC Transition | € 2.498.963 | 2023 | Details |
Real time Liver disease early diagnosis through exhaled Volatile Organic Compounds sensingDiaNose aims to revolutionize NAFLD diagnostics with a cost-effective, hand-held device using AI to classify breath chemical signatures, achieving >90% accuracy for improved patient outcomes. | EIC Transition | € 2.499.875 | 2024 | Details |
TraffikGene-Tx: Targeted Peptide Carriers for RNA Delivery
TraffikGene-Tx aims to develop safe, scalable peptide carriers for targeted RNA delivery, addressing genetic diseases and enhancing NAT therapies to improve patient outcomes and reduce healthcare costs.
Real time Liver disease early diagnosis through exhaled Volatile Organic Compounds sensing
DiaNose aims to revolutionize NAFLD diagnostics with a cost-effective, hand-held device using AI to classify breath chemical signatures, achieving >90% accuracy for improved patient outcomes.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Dry Powder Formulation of RNA Nanoparticles for Inhalation and Improved Storage and Transport ConditionsRNhale aims to develop a platform technology for spray-drying RNA nanoparticles to enhance stability and target delivery, ultimately seeking licensing agreements with pharmaceutical companies. | ERC Proof of... | € 150.000 | 2022 | Details |
Rational and Simulation-Supported Design of Inhalable RNA NanocarrierRatInhalRNA aims to design and optimize biocompatible siRNA nanoparticles for pulmonary delivery using a combination of DoE, MD simulations, and ML to enhance gene silencing efficacy. | ERC Consolid... | € 2.000.000 | 2023 | Details |
Kits for advanced polymer-lipid nanocarriers for targeted delivery of RNAs to cardiac and skeletal muscle cellsPOLIRNA aims to develop a versatile platform for safe and efficient RNA delivery to target multiple cell types, enhancing preclinical research in cardiac and muscle-related diseases. | ERC Proof of... | € 150.000 | 2023 | Details |
Smart RNA delivery for therapy and diagnosticThis project aims to develop peptide-based carriers for effective delivery of double-stranded RNA in cells, identifying candidates for potential commercial partnerships. | ERC Proof of... | € 150.000 | 2023 | Details |
Targeted Respiratory Drug Delivery by Tribo Charged SpraysDevelop a new technology for precise drug delivery to the lungs using charged droplets to prevent coalescence, enhancing treatment efficacy for conditions like lung cancer and COVID-19. | ERC Proof of... | € 150.000 | 2024 | Details |
Dry Powder Formulation of RNA Nanoparticles for Inhalation and Improved Storage and Transport Conditions
RNhale aims to develop a platform technology for spray-drying RNA nanoparticles to enhance stability and target delivery, ultimately seeking licensing agreements with pharmaceutical companies.
Rational and Simulation-Supported Design of Inhalable RNA Nanocarrier
RatInhalRNA aims to design and optimize biocompatible siRNA nanoparticles for pulmonary delivery using a combination of DoE, MD simulations, and ML to enhance gene silencing efficacy.
Kits for advanced polymer-lipid nanocarriers for targeted delivery of RNAs to cardiac and skeletal muscle cells
POLIRNA aims to develop a versatile platform for safe and efficient RNA delivery to target multiple cell types, enhancing preclinical research in cardiac and muscle-related diseases.
Smart RNA delivery for therapy and diagnostic
This project aims to develop peptide-based carriers for effective delivery of double-stranded RNA in cells, identifying candidates for potential commercial partnerships.
Targeted Respiratory Drug Delivery by Tribo Charged Sprays
Develop a new technology for precise drug delivery to the lungs using charged droplets to prevent coalescence, enhancing treatment efficacy for conditions like lung cancer and COVID-19.